A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT06921850. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Study identification
- NCT ID
- NCT06921850
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 43 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 9 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 6, 2025
- Primary completion
- Dec 20, 2026
- Completion
- Mar 5, 2029
- Last update posted
- Sep 10, 2026
2025 – 2029
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hs0006 50175 | Phoenix | Arizona | 85006 | — |
| Hs0006 50708 | Roseville | California | 95661 | — |
| Hs0006 50684 | Sacramento | California | 95815 | — |
| Hs0006 50707 | Washington D.C. | District of Columbia | 20010 | — |
| Hs0006 50199 | Miami | Florida | 33136 | — |
| Hs0006 50712 | Bowling Green | Kentucky | 42104 | — |
| Hs0006 50178 | Clarkston | Michigan | 48346 | — |
| Hs0006 50710 | Fort Gratiot | Michigan | 48059 | — |
| Hs0006 50711 | Troy | Michigan | 48084 | — |
| Hs0006 50706 | Chapel Hill | North Carolina | 27516 | — |
| Hs0006 50202 | Fairborn | Ohio | 45324 | — |
| Hs0006 50201 | Arlington | Texas | 76011 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06921850, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06921850 live on ClinicalTrials.gov.